Tom Wei‐Wu Chen

5.3k citations

91 papers · 2.0k indexed · 1 hit paper · h-index 19

Oncology top 2%
Pulmonary and Respiratory Medicine top 5%
Molecular Biology
Immunology top 10%
Cancer Research top 10%

Co-authors: Aaron R. Hansen L.L. Siu Daphne Day Leila Khoja Lillian L. Siu Philippe L. Bédard Ann‐Lii Cheng A.R. Abdul Razak
Topics: Sarcoma Diagnosis and Treatment (25 papers)Cancer Immunotherapy and Biomarkers (13 papers)Vascular Tumors and Angiosarcomas (11 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Immunology
Journals: Nature Communications The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: Taiwan China Canada

In The Last Decade

Tom Wei‐Wu Chen

83 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

2017 678 citations Tom Wei‐Wu Chen, Aaron R. Hansen et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Tom Wei‐Wu Chen

Since Specialization

Citations

This map shows the geographic impact of Tom Wei‐Wu Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Wei‐Wu Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Wei‐Wu Chen more than expected).

Fields of papers citing papers by Tom Wei‐Wu Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Wei‐Wu Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Wei‐Wu Chen. The network helps show where Tom Wei‐Wu Chen may publish in the future.

Co-authorship network of co-authors of Tom Wei‐Wu Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Wei‐Wu Chen. A scholar is included among the top collaborators of Tom Wei‐Wu Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Wei‐Wu Chen. Tom Wei‐Wu Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acyl post-translational modification of proteins by metabolites in cancer cells 2025 ·Cell Death Discovery ·Xudong Wang,Ying Guo,(unknown),(unknown),Tom Wei‐Wu Chen,Xinyu Tang,Yanlan Yu,Yicheng Chen,Guoqing Ding,Jie Zhang	1
2	Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications 2025 ·ImmunoTargets and Therapy ·Ying Guo,Xudong Wang,Chen Zhang,Tom Wei‐Wu Chen,(unknown),Yanlan Yu,Yicheng Chen,Tiejuan Shao,Jie Zhang,Guoqing Ding	7
3	Proteomic features of soft tissue tumours in adolescents and young adults 2024 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),(unknown),(unknown),Jessica Burns,(unknown),(unknown),Tom Wei‐Wu Chen,Khin Thway,Anguraj Sadanandam,Robin L. Jones,Paul H. Huang	2
4	Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma 2023 ·Breast Cancer Research ·Huang‐Chun Lien,Chia‐Lang Hsu,Yen‐Shen Lu,Tom Wei‐Wu Chen,(unknown),(unknown),Chiun‐Sheng Huang,Ann‐Lii Cheng,Ching‐Hung Lin	6
5	Delay of Surgery for Spinal Metastasis due to the COVID-19 Outbreak Affected Patient Outcomes 2023 ·Neurospine ·(unknown),Chun‐Yu Wu,Yen‐Heng Lin,Yucheng Huang,Wen-Chi Yang,Tom Wei‐Wu Chen,Weili Ma,Wei‐Hsin Lin,Feng‐Ming Hsu,Furen Xiao,Shih‐Hung Yang,Dar‐Ming Lai,Chang‐Mu Chen,(unknown),Fon-Yih Tsuang	4
6	Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer 2023 ·Breast Cancer Research and Treatment ·Tom Wei‐Wu Chen,(unknown),Ming‐Shen Dai,Ching‐Hung Lin,Dwan‐Ying Chang,I‐Chun Chen,Mingyang Wang,(unknown),Shu‐Min Huang,Ann‐Lii Cheng,(unknown),Kien Thiam Tan,Yen‐Shen Lu	5
7	Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis 2023 ·Cancer Medicine ·(unknown),Ching‐Hung Lin,I‐Chun Chen,Ying‐Chun Shen,Dwan‐Ying Chang,Tom Wei‐Wu Chen,Shu‐Min Huang,Fu‐Chang Hu,Yen‐Shen Lu	1
8	A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma 2022 ·Clinical Cancer Research ·Tom Wei‐Wu Chen,Chia‐Lang Hsu,Ruey‐Long Hong,Jen‐Chieh Lee,Koping Chang,Chih‐Wei Yu,San‐Chi Chen,(unknown),(unknown),(unknown),(unknown),Ann‐Lii Cheng,Chueh‐Chuan Yen	9
9	XPF activates break-induced telomere synthesis 2022 ·Nature Communications ·(unknown),(unknown),(unknown),Pei-Chen Chiu,(unknown),(unknown),Yunfei Chen,(unknown),(unknown),(unknown),(unknown),Tom Wei‐Wu Chen,Liuh‐Yow Chen,Ching-Shyi Wu,Jean‐Marc Egly,Hsueh‐Ping Chu	18
10	Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan 2022 ·Cancer ·Tom Wei‐Wu Chen,(unknown),A. Le Cesne,(unknown),Antoîne Italiano,Ya‐Wen Yang,Nicolas Penel,Wen‐Chung Lee,Emmanuelle Bompas,Thibaud Valentin,Philippe Anract,Nelly Firmin,Florence Duffaud,Ann‐Lii Cheng,Françoise Ducimetière,K. Arnold Chan,Jean‐Yves Blay	3
11	The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium 2021 ·Cancer Science ·Tom Wei‐Wu Chen,Angela Pang,Mark E. Puhaindran,(unknown),Herbert H. Loong,Virote Sriuranpong,(unknown),(unknown),Takeshi Hirose,Makoto Endo,Akira Kawai,Mohamad Farid,Sze Huey Tan,Wei Lin Goh,Richard Quek,Jeffrey Chan,(unknown),Roger K.C. Ngan	10
12	Optimal Clinical Management and the Molecular Biology of Angiosarcomas 2020 ·Cancers ·Tom Wei‐Wu Chen,Jessica Burns,Robin L. Jones,Paul H. Huang	14
13	When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma 2020 ·SHILAP Revista de lepidopterología ·(unknown),Tom Wei‐Wu Chen	2
14	Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components 2020 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Huang‐Chun Lien,(unknown),I‐Chun Chen,Ching‐Hung Lin,Tom Wei‐Wu Chen,(unknown),Yen‐Shen Lu	17
15	Primary Ewing Family of Tumor Arising in the Ovary: A Case Report 2018 ·International Journal of Gynecological Pathology ·Yiping Li,Koping Chang,Tom Wei‐Wu Chen,(unknown),Chi‐An Chen,Wen‐Fang Cheng	2
16	A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer 2017 ·Japanese Journal of Clinical Oncology ·Tom Wei‐Wu Chen,Dah‐Cherng Yeh,Tsu‐Yi Chao,Ching‐Hung Lin,(unknown),Dwan‐Ying Chang,(unknown),Shu‐Min Huang,Ann‐Lii Cheng,Yen‐Shen Lu	2
17	[New Hope for HER2-Positive Metastatic Breast Cancer Treatment: Trastuzumab Emtansine (T-DM1) From the Perspective of Nursing Care]. 2016 ·PubMed ·Hsiao-Hsuan Kuo,Tom Wei‐Wu Chen	3
18	Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy 2015 ·Clinical Cancer Research ·Yen‐Shen Lu,Tom Wei‐Wu Chen,Ching‐Hung Lin,Dah‐Cherng Yeh,Ling‐Ming Tseng,Pei‐Fang Wu,Kun‐Ming Rau,Bang‐Bin Chen,Ta‐Chung Chao,Shu‐Min Huang,Chiun‐Sheng Huang,Tiffany Ting‐Fang Shih,Ann‐Lii Cheng	71
19	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors 2015 ·Annals of Oncology ·Tom Wei‐Wu Chen,A.R. Abdul Razak,Philippe L. Bédard,Lillian L. Siu,Aaron R. Hansen	187
20	High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country 2015 ·PLoS ONE ·Ching‐Hung Lin,Chen‐Yang Shen,Jih‐Hsiang Lee,Chiun‐Sheng Huang,James Chih‐Hsin Yang,Wen‐Hung Kuo,Dwan‐Ying Chang,Chia‐Ni Hsiung,Kuan‐Ting Kuo,Tom Wei‐Wu Chen,I‐Chun Chen,Pei‐Fang Wu,Sung‐Hsin Kuo,Chien‐Jen Chen,Yen‐Shen Lu,Ann‐Lii Cheng	9

About Tom Wei‐Wu Chen

Tom Wei‐Wu Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 91 papers that have together received 2.0k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (25 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Vascular Tumors and Angiosarcomas (11 papers). The work is most often cited by research in Oncology (1.4k citations), Pulmonary and Respiratory Medicine (745 citations) and Immunology (387 citations). Tom Wei‐Wu Chen has collaborated with scholars based in Taiwan, China and Canada. Frequent co-authors include Aaron R. Hansen, L.L. Siu, Daphne Day, Leila Khoja, Lillian L. Siu, Philippe L. Bédard, Ann‐Lii Cheng, A.R. Abdul Razak, Yen‐Shen Lu and Ching‐Hung Lin. Their work appears in journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact